drugset / Trial / NCT01801228
Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
Phase 2
Withdrawn
Emma Nilsson
Göteborg University · collabKarolinska University Hospital · collabRegion Örebro County · collabUniversity Hospital, Linkoeping · collabUniversity Hospital, Umeå · collabUppsala University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone, a selective aldosterone antagonist, regarding efficacy and hormonal side effects when treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment of ascites with less side effects such as painful gynecomastia.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eplerenone | Unknown | 100 mg | Oral |
| Subject | Eplerenone | Unknown | 400 mg | Oral |